15 Biotech VCs Who Funded $8B in Exits Last Year in 2026

Biotech investors are venture capital firms that fund drug development, therapeutics platforms, and life sciences companies from bench science through clinical trials and commercialization. I run Peony (a data room platform starting free), and biotech founders are among our most document-intensive users: target product profiles, CMC plans, preclinical data packages, regulatory filings, and IP analyses that need to reach the right investors without leaking to competitors.

TL;DR: Biotech VC fundraising hit record levels in 2024-2025 -- ARCH raised $3B+, Flagship raised $3.6B, Bain Capital Life Sciences raised $3B, and Vida Ventures delivered four Big Pharma exits totaling over $8B in a single year. The 15 firms below range from seed-stage company creators (ARCH, Flagship, Third Rock) to growth-stage crossover investors (Bain Capital, RA Capital, Samsara BioCapital). Organize your fundraising materials with Peony (free, $0) -- AI auto-indexing handles TPPs, CMC plans, and preclinical data in under 3 minutes, and page-level analytics show which investors actually reviewed your mechanism of action data.

Last updated: April 2026

One pattern I keep seeing from biotech founders on our platform: the ones who close fastest are not the ones with the flashiest science. They are the ones who show up with a clean data room -- target product profile, killer experiment, CMC outline, IP map -- organized so that an investor partner can get to conviction in a single session. Last quarter, a Series A founder sharing preclinical oncology data through Peony told me that our page-level analytics showed three of her twelve target investors spent over 30 minutes on her CMC section. She focused her follow-ups on those three and closed her round in eight weeks. That signal -- knowing who actually dug into your science versus who skimmed your deck -- matters more in biotech than in any other sector, because the diligence is deeper and the stakes are higher.

For digital health, medtech, and care delivery investors, see Top 9 Healthcare Investors.

15 Top Biotech VCs at a Glance

How to Pick the Right Biotech VC

Not all biotech capital is interchangeable. Your bottleneck determines which investor to approach first.

If you need company creation and lab build-out, look for hands-on builders who co-found companies from scientific discoveries: ARCH, Third Rock, Flagship, Versant, Atlas, Omega. These firms assign operating partners, recruit founding teams, and fund from bench to IND.

If you need large staged financings and crossover discipline, target investors who can write checks from Series A through IPO: RA Capital, Bain Capital Life Sciences, Foresite, Samsara BioCapital. These firms bridge private and public markets, reducing the fundraising burden at each transition.

If you need European reach, prioritize Sofinnova Partners (Paris, London, Milan) and Omega Funds (New York plus London). Both have deep scientific networks across the EU and invest transatlantically.

If you need pharma exit networks, study Vida Ventures (four Big Pharma acquisitions in 2025 alone) and Versant (100+ successful exits including acquisitions and IPOs since 1999).

Prioritize recency over brand. Scan the last 12-18 months of fund closes, new company launches, and portfolio exits. A big name with a depleted fund is less useful than a smaller firm that just closed fresh capital.

Arrive with proof. Even at pre-Series A: a crisp target product profile, the single experiment that changes belief, a translational plan from assay to model to IND, a CMC outline, IP and freedom-to-operate analysis, and a milestone-indexed capital plan. Organize everything in a secure data room so investors can self-serve their diligence -- Peony AI auto-indexing categorizes your documents in under 3 minutes.

Detailed Profiles: 15 Biotech VCs

1. ARCH Venture Partners

ARCH co-founds companies directly with university researchers and scientists. They start at the bench -- working with academic labs to translate discoveries into companies. Robert Nelsen was named to STAT's 2025 STATUS List. The firm has 279 portfolio companies as of early 2026, with 50+ reaching $1B+ valuations.

Recent signals: Co-incubated Xaira Therapeutics ($1B founding round) for AI drug discovery with Foresite Labs. Orbital Therapeutics was acquired by Bristol Myers Squibb for $1.5B in October 2025.

They scrutinize: Mechanism of action truth set, founder quality, decisive proof-of-concept path.

Best approach: One-page TPP plus a 12-month "truth plan" (assay to model to IND). ARCH wants to see the science first and the business case second.

2. Flagship Pioneering

Flagship does not invest in existing companies. It internally originates 80-100 "explorations" per year through Flagship Labs, then systematically evolves them: Explorations to ProtoCos to NewCos to GrowthCos. This model produced Moderna. Over 100 first-in-category bioplatform companies created since inception, generating over $100B in aggregate value.

Recent signals: Launched Expedition Medicines ($50M founding capital, AI-powered drug discovery, Oct 2025) and Lila Sciences (superintelligence in science, Mar 2025). Partnerships with Pfizer, Novo Nordisk, GSK, and Genentech. More than 50 drugs in clinical development across the portfolio.

They scrutinize: Engine repeatability, manufacturability, platform differentiation.

Best approach: Frame your platform "factory" economics plus a 24-month product slate. Flagship thinks in systems, not single assets.

3. Third Rock Ventures

Third Rock builds companies from scratch -- they recruit founding teams, provide initial capital, and serve as active operating partners. Topped STAT's biotech VC rankings in 2025. The firm has created 72 companies and generated 19 IPOs and 23 acquisitions.

Recent signals: Syremis Therapeutics ($165M Series A, mental health medicines, Dec 2025). Azalea Therapeutics ($82M, precision genome engineering in vivo, Nov 2025). Tango Therapeutics ($225M financing, cancer programs, Q3 2025).

They scrutinize: Biomarker strategy, first clinical experiment that changes belief.

Best approach: Founding plan with specific personnel and timeline, board-grade milestones, and explicit kill-gates. Third Rock partners expect governance maturity from day one.

4. Atlas Venture

Atlas runs a deliberate two-fund model: one fund seeds and co-founds new biotech companies, while a separate Opportunity Fund provides follow-on capital for later-stage rounds and public market support. Bruce Booth's LifeSciVC blog is one of the most widely read sources in biotech venture. Atlas could have raised "several multiples" of their Fund XIV hard cap.

Recent signals: Launched Antares Therapeutics and Renasant Bio in 2025. Closed $400M Opportunity Fund III in September 2025. 56 active portfolio companies with 147 programs in pipeline, roughly 50 in clinic. Rare disease (36% of portfolio) and oncology (31%) are top focus areas.

They scrutinize: Indication math, fast-fail gates, capital efficiency.

Best approach: 12-month truth plan, minimal senior team, vendor and CDMO map. Atlas prizes discipline over ambition.

5. Versant Ventures

Versant operates a "Frontier Discovery Engine" spanning Toronto and Montreal that forms companies using novel drug modalities -- gene therapy, gene editing, cell therapy, and precision oncology. The three-fund structure ($560M company formation, $140M early co-invest, $250M later-stage follow-on) supports companies from formation through exit. Over 100 portfolio companies have achieved successful acquisitions or IPOs since 1999.

Recent signals: Launched Dayra Therapeutics ($70M+ committed, $50M Biogen partnership, oral macrocyclic peptides, Nov 2025). Granite Bio ($100M debut, 2 immune drugs). Dualitas Therapeutics (Series A, Sep 2025). Gate Bioscience (AI-driven biology platforms).

They scrutinize: Chemistry and biology integration, CMC realism, early win/kill experiment designs.

Best approach: Inception-to-IND plan showing how your discovery engine accelerates learning, not burn. Versant values capital efficiency in company formation.

6. Vida Ventures

Vida had arguably the best single year of any biotech VC in history. Four portfolio companies were acquired by Big Pharma in 2025 for aggregate deal value exceeding $8B:

• Halda Therapeutics -- acquired by J&J for $3.05B (largest-ever acquisition of a Phase 1 company)
• Scorpion Therapeutics -- acquired by Eli Lilly for up to $2.5B
• Capstan Therapeutics -- acquired by AbbVie for $2.1B upfront
• Vigil Neuroscience -- acquired by Sanofi for $470M upfront plus CVR

Founded by Arie Belldegrun, who previously built Kite Pharma (CAR-T pioneer, sold to Gilead for $11.9B). Science-first, discipline-driven strategy with deep oncology and immunology expertise. Recently expanded into public market investing (Matt Cohen from JPM Asset Management) and company creation (Brian Goodman from MPM BioImpact).

They scrutinize: Clinical differentiation, translation quality, pharma acquirer rationale.

Best approach: Show the exit thesis early. Vida thinks about which pharma would acquire your asset, and why, from the very first meeting.

7. RA Capital Management

RA Capital is a public-private crossover investor -- they invest from private seed rounds through IPO and beyond into the public markets. Peter Kolchinsky (author of "The Great American Drug Deal") is one of the most publicly visible biotech investors. RA also provides structured lending, giving portfolio companies multiple financing options beyond equity.

Recent signals: Funded $250M senior secured term loan for ARS Pharmaceuticals (Sep 2025). Top Q4 2025 holdings include Ascendis Pharma, Cidara Therapeutics, Rhythm Pharmaceuticals, and Vaxcyte. 71 total holdings in latest SEC filing.

They scrutinize: Human relevance of preclinical data, comparator mechanisms, probability-weighted valuation.

Best approach: Evidence table tying genetics to biomarkers to animal models, with a sober risk register. RA Capital does deep quantitative diligence and respects founders who do the same.

8. Foresite Capital

Foresite operates Foresite Labs, an in-house incubation arm that co-founds companies at the intersection of AI and biology. Jim Tananbaum (Midas List honoree) brings a quantitative, data-driven approach to biotech investing. The firm bridges early-stage creation via Foresite Labs with growth-stage crossover investing via the flagship fund.

Recent signals: Co-incubated Xaira Therapeutics ($1B founding round) with ARCH. Backed Latigo Biotherapeutics ($135M Series A, non-opioid pain treatment). Alumis (clinical-stage autoimmune). Element Biosciences (genomic sequencing).

They scrutinize: Inflection-point planning, payer-relevant endpoints, data quality.

Best approach: Milestone-indexed plan tying datasets to valuation step-ups. Foresite values computational rigor in drug development.

9. Bain Capital Life Sciences

Bain Capital Life Sciences deploys larger checks at later stages than most biotech VCs, targeting "inflection capital" -- funding companies at critical clinical, regulatory, or commercial milestones. Backed by Bain Capital's 40-year healthcare investing history. Since inception: 70+ companies invested, 100+ clinical trials initiated, 16 regulatory approvals.

Recent signals: Kailera Therapeutics (Series B, Oct 2025). Seran Bioscience ($200M strategic growth transaction), Sep 2024. HeartFlow (portfolio exit, Aug 2025). Strong global presence with Shanghai office targeting China opportunities.

They scrutinize: Clinical inflection timing, commercial readiness, scale manufacturing feasibility.

Best approach: If you are pre-Phase 2, Bain Capital is likely too early for you. Approach when you have clinical data that de-risks a major inflection -- Phase 2 readout, regulatory milestone, or commercial launch preparation.

10. Sofinnova Partners

Sofinnova is Europe's premier life sciences VC. They operate multiple strategies: Capital (flagship early-stage biopharma and medtech), MD Start (medtech accelerator), Crossover (growth-stage), and Biovelocita (biotech acceleration backed by Amgen, BMS, and Pfizer Ventures). 20+ successful exits over the past decade, 30+ approved products reaching patients.

Recent signals: Capital XI initial investments include Actithera (next-gen radiotherapeutics), Elevara (novel RA therapies), Haya Therapeutics (RNA-based platform), and NanoPhoria (inhalable nanoparticles). Biovelocita II (EUR 165M) backed by three Big Pharma corporate venture arms. Historical exits include Shockwave (acquired by J&J for $13.1B).

They scrutinize: European regulatory strategy, clinical site network, manufacturing partnerships.

Best approach: If you are a European biotech founder, Sofinnova should be at the top of your list. For US founders, Sofinnova is the bridge to European clinical development and partnership networks.

11. Omega Funds

Omega focuses exclusively on "transformative, not incremental innovation" -- they only invest in companies targeting severe unmet medical needs. Transatlantic presence (NYC plus London) gives access to both US and European biotech ecosystems. The firm both creates and invests in companies, averaging 6 new investments per year over the last decade. 150+ innovative life sciences companies invested since inception.

Recent signals: Ousia Pharma (most recent first-time investment, 2025). NRG Therapeutics (mitochondrial therapeutics for Parkinson's and ALS, follow-on 2025). CDR-Life (tumor-specific immuno-oncology). 10 investments in 2024; 5 in 2025 as of September.

They scrutinize: Severity of unmet need, translational evidence, differentiation versus incremental improvement.

Best approach: Lead with the patient population and unmet need. Omega is not interested in me-too drugs or marginal improvements. Show transformative potential backed by rigorous preclinical evidence.

12. 5AM Ventures

5AM discovers, incubates, and invests in breakthrough life science companies. Scott Rocklage brings direct pharma operating experience -- three FDA NDA approvals as CEO of Cubist Pharmaceuticals (developer of Cubicin). Two-fund model similar to Atlas: core fund seeds new companies, Opportunities fund provides follow-on capital. 96 companies invested since founding with 60 portfolio exits. Strong West Coast ties to Stanford, UCSF, and Bay Area academic institutions.

Recent signals: 9 new investments in 2025. Backed Latigo Biotherapeutics ($135M, non-opioid pain medicine, co-invested with Foresite). Active across seed and Series A with consistent annual deal pace.

They scrutinize: Differentiation versus class peers, IND-enablement realism, CMC risk mitigations.

Best approach: IND package outline, assay validation plan, and manufacturing risk mitigations. 5AM values operational realism from partners who have run FDA approvals themselves.

13. Polaris Partners

Polaris operates the Innovation Fund, a dedicated vehicle that systematically spins academic biomedical research into companies in partnership with world-class scientists. This academic spinout engine, led by Amy Schulman, differentiates them from peers. Terry McGuire brings 35+ years of founding-partner experience. Amir Nashat is particularly prolific in company creation (Dewpoint Therapeutics, Fate Therapeutics, Jnana Therapeutics).

Recent signals: Led Leyden Labs ($70M Series B) with Casdin Capital. Sequelae (Series A-II, Nov 2025). 18 investments in 2024; 7 in 2025 as of November. Targeting $500M for latest fund.

They scrutinize: Academic translation quality, scientific founder commitment, IP assignment clarity.

Best approach: If your science originates from academic research, Polaris is a natural fit. Come with a clear IP assignment path, founding team commitment plan, and first 18 months of translational milestones.

14. Samsara BioCapital

Samsara is a public-private crossover investor that provides capital "throughout the entire risk cycle" for both private and public life sciences companies. Founded in 2016 by Srinivas Akkaraju (MD/PhD from Stanford). Smaller AUM relative to peers like RA Capital means more concentrated, higher-conviction positions. Strong oncology and immunology focus. 135 total investments. Dr. Akkaraju serves on boards of Scholar Rock, Mineralys Therapeutics, and vTv Therapeutics.

Recent signals: Top holdings include Scholar Rock, Mineralys Therapeutics, Kalaris Therapeutics, Septerna, and Alumis. 16 investments in 2024; 7 in 2025 as of October.

They scrutinize: Mechanism differentiation, clinical probability of success, public market readiness.

Best approach: Samsara is ideal if you want an investor who will stay with you through IPO and beyond. Demonstrate not just your private-round thesis but your public-market narrative.

15. Deerfield Management

Deerfield operates the "Cure" campus in NYC, a physical innovation hub that nurtures biotech startups alongside close collaboration with a network of nearly 30 academic institutions. The firm spans public equity, private venture, structured lending, and innovation investing. Closed over $600M for Healthcare Innovations Fund III targeting therapeutics and emerging biotech technologies. 226 portfolio companies including 3 unicorns.

Recent signals: Perceive Pharma (Series A, eye drug developer, 2025). Bambusa Therapeutics (funding round, Feb 2025). Axon Therapies ($32M Series A, Sep 2025). BridgeBio Oncology Therapeutics, Frontier Medicines, Elion Therapeutics (2024 investments).

They scrutinize: Execution risk (manufacturing and supply), regulatory path clarity, risk-adjusted NPV logic.

Best approach: Come with a Gantt chart showing resourcing, CDMO selection, contingencies, and governance structure. Deerfield expects institutional-grade execution planning.

Five Tips for Pitching Biotech VCs

1. Lead with the TPP and killer experiment. One slide that ties patient benefit to the single experiment that changes belief -- what it is, when it runs, and what the readout means for go/no-go.

2. Treat CMC as product. Name your process, analytics, release specs, CDMO plan, and the two biggest manufacturing risks with mitigations. Investors who have seen clinical-stage companies fail on CMC will notice if you skip this.

3. Be comparator-honest. Put standard of care and late-stage competitors on one table. Justify your endpoints and payer relevance. Do not hide the competitive landscape -- the investor will find it during diligence anyway.

4. Map capital to learning, not timelines. "With $X we will achieve Y truths (IND, first-in-human, biomarker readout) and Z options (BD, indication expansion)." This framing shows you think in milestones, not months.

5. Run a tight process. Clean IP map, study reports, assay validation data, tox plan, vendor letters, SAB and KOL references, and a tidy data room index. Make "yes" easy. Organize your biotech data room with Peony -- AI auto-indexing handles the folder structure, page-level analytics show which investors reviewed your CMC section, and screenshot protection prevents unauthorized distribution of preclinical data. Set up in under 5 minutes on the free tier, or use Business ($40/admin/month) for NDA gates and dynamic watermarks.

How Peony Helps Biotech Founders Raise Capital

Biotech fundraising involves more sensitive documentation than almost any other vertical: preclinical data packages, regulatory filings, patent applications, CMC plans, and clinical protocols. Sharing these with 10-15 VCs simultaneously requires security controls that consumer file-sharing tools cannot provide.

Peony is built for exactly this workflow:

• AI auto-indexing categorizes TPPs, CMC plans, assay data, and regulatory filings into a professional data room structure in under 3 minutes (learn more)
• Page-level analytics show which investors spent the most time on which sections -- so you know who dug into your MOA data versus who just browsed the pitch deck (learn more)
• Screenshot protection blocks and logs capture attempts on sensitive preclinical data (learn more)
• Dynamic watermarks embed viewer identity into every rendered page, deterring unauthorized sharing (learn more)
• NDA gates require investors to sign before accessing your data room (learn more)
• AI document extraction lets investors ask natural-language questions across your entire data room and get cited answers with exact page numbers

Free tier available. Pro at $20/admin/month. Business at $40/admin/month with full security suite. See pricing.

Frequently Asked Questions

Who are the top biotech VCs in 2026?

The top biotech VCs in 2026 include ARCH Venture Partners ($3B+ Fund XIII), Flagship Pioneering ($3.6B raised in 2024), Third Rock Ventures (ranked number 1 by STAT), Atlas Venture ($450M Fund XIV plus $400M Opportunity Fund III), Versant Ventures ($950M across three vehicles), and Vida Ventures (four Big Pharma exits totaling over $8B in 2025). These firms primarily create new biotech companies from scientific discoveries rather than investing in existing startups. Peony page-level analytics show which investors spent the most time on your TPP and CMC documentation, so you can prioritize follow-ups with genuinely interested firms.

How much capital did biotech VCs raise in 2024 and 2025?

Biotech VC fundraising hit record levels. ARCH closed Fund XIII at over $3B in September 2024. Flagship raised $3.6B in July 2024. Bain Capital Life Sciences closed Fund IV at $3B in September 2024. Versant raised $950M across three vehicles. Sofinnova Partners closed Capital XI at EUR 650M in November 2025. Omega Funds closed Fund VIII at $647M in July 2025. Deerfield closed Healthcare Innovations Fund III at over $600M in May 2025. Peony data rooms let biotech founders organize pitch materials in under 5 minutes, so you spend time on science instead of folder structures.

What documents do biotech investors need for due diligence?

Biotech investors expect a target product profile, mechanism of action summary, preclinical data package with assay validation, CMC outline with CDMO plan, IP and freedom-to-operate analysis, regulatory strategy with IND timeline, clinical development plan with endpoints and enrollment projections, financial model with milestone-indexed capital plan, and cap table. Peony AI auto-indexing categorizes all of these file types into a professional data room structure in under 3 minutes, and dynamic watermarks with viewer identity protect sensitive preclinical data when sharing with multiple VCs simultaneously.

What is the difference between biotech VCs and healthcare investors?

Biotech VCs focus specifically on drug development, therapeutics, genomics, and life sciences platform companies. They evaluate mechanism of action, clinical trial design, CMC feasibility, and regulatory pathways. Healthcare investors have a broader mandate covering digital health, medical devices, care delivery, health IT, and insurance technology alongside therapeutics. Firms like ARCH, Flagship, and Third Rock are pure-play biotech company creators, while firms like OrbiMed and Deerfield span multiple healthcare sectors. Peony screenshot protection blocks and logs capture attempts on sensitive clinical data, which biotech founders sharing Phase 1 results with multiple investors find essential.

How should I pitch a biotech VC?

Lead with your target product profile and the single experiment that changes belief about your mechanism. Treat CMC as product by naming your process, analytics, release specs, CDMO plan, and the two biggest manufacturing risks with mitigations. Put standard of care and late-stage comparators on one honest table with justified endpoints and payer relevance. Map capital to learning milestones, not arbitrary timelines. Run a tight process with a clean IP map, assay validation data, tox plan, and KOL references organized in a secure data room. Peony NDA gates require investors to sign before accessing your preclinical data, adding a layer of IP protection from the first touchpoint.

Which biotech VCs create new companies versus investing in existing startups?

At least seven of the top 15 biotech VCs primarily create new companies rather than investing in existing startups. ARCH co-founds companies from university research. Flagship internally originates 80 to 100 explorations per year through Flagship Labs. Third Rock recruits founding teams and provides initial capital. Atlas seeds and co-founds through its core fund. Versant forms companies through its Frontier Discovery Engine. Omega creates and invests across the US and Europe. Polaris spins academic research into companies through its Innovation Fund. These company creators expect founders to arrive with a one-page TPP and a 12-month truth plan. Peony AI document extraction lets investors ask natural-language questions across your entire data room and get cited answers with exact page numbers.

Related Resources

• Biotech Data Room Guide (9-Folder Checklist)
• Startup Data Room Checklist
• Top 9 Healthcare Investors
• 15 Health Tech VCs That Actually Led Rounds in 2026
• How to Send Your Pitch Deck to Investors
• Track Pitch Deck Engagement
• Best Data Rooms for Startups
• Data Room for Investors
• Startup Fundraising Rounds Guide